

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1-55. (canceled)

56. (currently amended) A method for inhibiting angiogenesis in a mammal comprising administering to the mammal an effective amount of an antibody or antigen binding fragment thereof that specifically binds and neutralizes:

- a) a polypeptide comprising an amino acid sequence of SEQ ID NO:76; and/or
- b) an immunogenic fragment ~~of a protein of the polypeptide comprising the amino acid sequence of SEQ ID NO:76, wherein the fragment comprises comprising at least thirty ten contiguous amino acids sequence of SEQ ID NO:76 to the mammal , wherein said fragment can generate or select an antibody that specifically binds the polypeptide comprising the amino acid sequence of SEQ ID NO:76.~~

57-68. (canceled)

69. (previously presented) The method of claim 56, wherein the polypeptide is encoded by a polynucleotide comprising a nucleic acid sequence of SEQ ID NO:75.

70. (currently amended) The method of claim 56, wherein said antibody is a polyclonal antibody, a monoclonal antibody, an antibody fragment[[s]], a human antibody, a humanized antibody, a chimeric antibody, a bispecific antibody or a heteroconjugate ~~heteroconjugate~~ antibody.

71. (currently amended) The method of claim 70, wherein said antibody is an antagonist or a neutralizing antibody.

72. (previously presented) The method of claim 56, wherein the antibody has polyepitopic specificity.

73. (currently amended) The method of claim 56, wherein the antibody is a human antibody, a chimeric antibody, or a humanized antibody.

74. (previously presented) The method of claim 56, wherein the antibody is an antibody fragment.

75. (currently amended) The method of claim 74, wherein the antibody fragment comprises a Fab fragment, a Fab' fragment, a F(ab')₂ fragment, or a Fv fragment.

76. (previously presented) The method of claim 56, wherein the antibody is a heteroconjugate antibody.